David Mott

David Mott

Chairman at ARDELYX, INC.

Net worth: 21 M $ as of 30/05/2026

60 year
Health Technology
Finance
Consumer Services

Profile

Mr. David M.
Mott
is an Independent Director at Novavax, Inc., a Chairman at Ardelyx, Inc. and a Chairman at Cydan LLC.
He is on the Board of Directors at Novavax, Inc., Biotechnology Innovation Organization, NEA 14 GP Ltd. and XTuit Pharmaceuticals, Inc. Mr. Mott was previously employed as a Chairman by Imara, Inc., an Independent Director by Clementia Pharmaceuticals, Inc., an Independent Non-Executive Director by Nightstar Therapeutics Plc, a Chairman by Adaptimmune Ltd., a Chairman by Adaptimmune Therapeutics Plc, a Chairman by Mersana Therapeutics, Inc., a Chairman-Supervisory Board by Prosensa Holding NV, a Chairman by Epizyme, Inc., a General Partner by NEA Management Co. LLC, a General Partner by New Enterprise Associates LLC, a Non-Executive Director by Shire Plc, an Executive Vice President by AstraZeneca PLC, a President by MedImmune Ventures, Inc., a Vice Chairman, President & Chief Executive Officer by MedImmune LLC, a President & Chief Executive Officer by MedImmune Ltd., a Vice President-Health Care Investment Banking by Smith Barney Harris Upham & Co., Inc., a Chairman by Complexa, Inc., a Chairman by Conceptis Technologies, Inc., a Chairman by Cydan II, Inc., a VP-Health Care Investment Banking Group by Harris Upham & Co, Inc., a Chairman by Sagimet Biosciences, Inc., a Member-Governing Board by St. Albans School, a Trustee by St. James' School, a Chairman by Vtesse, Inc., and a Chairman by Zyngenia, Inc. He also served on the board at Polyneuron Pharmaceuticals AG, Tiburio Therapeutics, Inc., Omthera Pharmaceuticals, Inc., Tesaro, Inc., Ambit Biosciences Corp., Biohealth Innovation, Inc., Edimer Pharmaceuticals, Inc., Melinta Subsidiary Corp., NightstaRx Ltd., Shire Pharmaceuticals, Inc., Shire Plc /Old/, Zosano Pharma Corp.
and ZP Opco, Inc. He received his undergraduate degree from Dartmouth College.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
30/03/2026 3,302,918 ( 1.34% ) 20 M $ 30/05/2026
22/04/2026 79,770 ( 0.05% ) 875 077 $ 30/05/2026
10/04/2025 0 ( -.--% ) - $ 30/05/2026
05/01/2026 0 ( -.--% ) - $ 30/12/2025

David Mott active positions

CompaniesPositionStart
ARDELYX, INC. Chairman 28/02/2014
NOVAVAX, INC. Director/Board Member 15/06/2020
Chairman -
NEA 14 GP Ltd.
Director/Board Member -
Director/Board Member -
Director/Board Member -

Former positions of David Mott

CompaniesPositionEnd
MERSANA THERAPEUTICS Chief Executive Officer 01/03/2015
ADAPTIMMUNE THERAPEUTICS PLC Chairman 13/11/2025
IMARA Chairman 31/01/2023
░░░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░ ░░░░░░░░░░ ░░░ ░░░ ░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░
See the detail of David Mott's experience

Training of David Mott

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

58

1st degree connections

45

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies45

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Technology Services

Finance

Health Technology

Health Technology

Health Technology

Commercial Services

Health Technology

Retail Trade

Health Technology

Health Technology

Consumer Services

Finance

Health Technology

Finance

Consumer Services

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Consumer Services

NEA 14 GP Ltd.

Health Technology

Health Technology

Distribution Services

Finance

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!